Advertisement
Singapore markets open in 6 hours

  • Straits Times Index

    3,296.89
    +4.20 (+0.13%)
     

  • S&P 500

    5,069.23
    +50.84 (+1.01%)
     

  • Dow

    38,264.02
    +360.73 (+0.95%)
     

  • Nasdaq

    15,848.41
    +242.93 (+1.56%)
     

  • Bitcoin USD

    59,445.54
    +374.18 (+0.63%)
     

  • CMC Crypto 200

    1,277.22
    +6.48 (+0.51%)
     

  • FTSE 100

    8,172.15
    +50.91 (+0.63%)
     

  • Gold

    2,317.00
    +6.00 (+0.26%)
     

  • Crude Oil

    79.16
    +0.16 (+0.20%)
     

  • 10-Yr Bond

    4.5750
    -0.0200 (-0.44%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,207.13
    +444.10 (+2.50%)
     

  • FTSE Bursa Malaysia

    1,580.30
    +4.33 (+0.27%)
     

  • Jakarta Composite Index

    7,117.42
    -116.77 (-1.61%)
     

  • PSE Index

    6,646.55
    -53.94 (-0.81%)
     

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

scPharmaceuticals, Inc.
·1-min read
scPharmaceuticals, Inc.
scPharmaceuticals, Inc.

BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences.

Events:

TD Cowen 44th Annual Health Care Conference
Wednesday, March 6, 2024
Fireside Chat: 12:50 p.m. EST

Leerink Partners Global Biopharma Conference
Tuesday, March 12, 2024
Presentation: 2:20 p.m. EST

ADVERTISEMENT

A live webcast of both presentations can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scPharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
ktaudvin@scpharma.com

Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7579
pkelleher@lifesciadvisors.com